Som en svag hæmmer af CYP3A4 kan aprepitant (40 mg) øge plasmakoncentrationen af samtidigt oralt administrerede aktive substanser, som metaboliseres gennem CYP3A4.
Effect of CYP3A4 inhibition by aprepitant on the pharmacokinetics of other active substances As a weak inhibitor of CYP3A4, aprepitant (40 mg) can increase plasma concentrations of orally co-administered active substances that are metabolised through CYP3A4.